Astellas Sues Roxane Over Generic Cancer Drug ANDA
Astellas Pharma Inc. is accusing Roxane Laboratories Inc. of filing an abbreviated new drug application for a generic version of its prostate cancer treatment Xtandi that infringes three of its unexpired...To view the full article, register now.
Already a subscriber? Click here to view full article